In lung adenocarcinoma, oncogenic KRAS mutations are highly prevalent (~25 %) but therapy choices are very limited (reviewed in [49]) indicating that our findings might be of relevance to improve treatment of a significant fraction of lung adenocarcinoma patients. Here, KRAS is linked to lung adenocarcinoma.